Passage Bio Inc (NAS:PASG)
$ 0.657 -0.0029 (-0.44%) Market Cap: 40.58 Mil Enterprise Value: -18.43 Mil PE Ratio: 0 PB Ratio: 0.56 GF Score: 36/100

Passage Bio, Inc. - Special Call Transcript

Jan 25, 2021 / 04:00PM GMT
Release Date Price: $20.92 (+5.60%)
Bruce A. Goldsmith
Passage Bio, Inc. - CEO, President & Director

Thank you all for joining us today. We are very excited to host the first of a series of discussions in our R&D webinar series. The first will obviously focus on our lead program, PBGM01 in GM1 gangliosidosis. And I can't tell you how excited we are for the opportunity to talk about both Passage Bio and we -- how we are continuing to execute our vision to fill the promise of gene therapies for CNS disorders.

In addition to myself and our Chief Medical Officer, Gary Romano, I am very pleased that joining us will be Jim Wilson, Director of the Gene Therapy Program at University of Pennsylvania and our Chief Scientific Adviser and obviously, Co-Founder of the company; as well as Christian Hinderer who is our Senior Research Director of Translational Research at the Gene Therapy Program.

Before we begin on Slide 2, I remind you that we will be making forward-looking statements and to refer to our SEC filings for additional information. On Slide 3, I want to pause briefly on the agenda. After I give a brief overview of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot